{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:41:56Z","timestamp":1780987316279,"version":"3.54.1"},"reference-count":205,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Unconventional T cells and innate lymphoid cells (ILCs) make up a heterogeneous set of cells that characteristically show prompt responses toward specific antigens. Unconventional T cells recognize non-peptide antigens, which are bound and presented by diverse non-polymorphic antigen-presenting molecules and comprise \u03b3\u03b4 T cells, MR1-restricted mucosal-associated invariant T cells (MAITs), and natural killer T cells (NKTs). On the other hand, ILCs lack antigen-specific receptors and act as the innate counterpart to the T lymphocytes found in the adaptive immune response. The alteration of unconventional T cells and ILCs in frequency and functionality is correlated with the onset of several autoimmune diseases, allergy, inflammation, and tumor. However, depending on the physio-pathological framework, unconventional T cells may exhibit either protective or pathogenic activity in a range of neoplastic diseases. Nonetheless, experimental models and clinical studies have displayed that some unconventional T cells are potential therapeutic targets, as well as prognostic and diagnostic markers. In fact, cell-mediated immune response in tumors has become the focus in immunotherapy against neoplastic disease. This review concentrates on the present knowledge concerning the function of unconventional T cell sets in the antitumor immune response in hematological malignancies, such as acute and chronic leukemia, multiple myeloma, and lymphoproliferative disorders. Moreover, we discuss the possibility that modulating the activity of unconventional T cells could be useful in the treatment of hematological neoplasms, in the prevention of specific conditions (such as graft versus host disease), and in the formulation of an effective anticancer vaccine therapy. The exact knowledge of the role of these cells could represent the prerequisite for the creation of a new form of immunotherapy for hematological neoplasms.<\/jats:p>","DOI":"10.3390\/biom12060754","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T01:40:45Z","timestamp":1653702045000},"page":"754","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-8239","authenticated-orcid":false,"given":"Alessandro","family":"Allegra","sequence":"first","affiliation":[{"name":"Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, Division of Hematology, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5436-1501","authenticated-orcid":false,"given":"Marco","family":"Casciaro","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5401-4545","authenticated-orcid":false,"given":"Elena","family":"Lo Presti","sequence":"additional","affiliation":[{"name":"National Research Council (CNR)\u2014Institute for Biomedical Research and Innovation (IRIB), 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Musolino","sequence":"additional","affiliation":[{"name":"Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, Division of Hematology, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Gangemi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/s41467-018-04076-0","article-title":"The human V\u03b42+ T-cell compartment comprises distinct innate-like V\u03b39+ and adaptive V\u03b39\u2212 subsets","volume":"9","author":"Davey","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s41590-019-0444-8","article-title":"The biology and functional importance of MAIT cells","volume":"20","author":"Godfrey","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jaci.2016.09.011","article-title":"Innate lymphoid cells in allergic and nonallergic inflammation","volume":"138","author":"Morita","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00018-015-2055-3","article-title":"Innate lymphoid cells in intestinal immunity and inflammation","volume":"73","author":"Bostick","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/jid.2014.146","article-title":"Composition of Innate Lymphoid Cell Subsets in the Human Skin: Enrichment of NCR + ILC3 in Lesional Skin and Blood of Psoriasis Patients","volume":"134","author":"Teunissen","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"789788","DOI":"10.3389\/fimmu.2021.789788","article-title":"Innate Lymphoid Cells in Autoimmune Diseases","volume":"12","author":"Clottu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.imlet.2005.06.025","article-title":"V\u03b39V\u03b42 T cell-mediated non-cytolytic antiviral mechanisms and their potential for cell-based therapy","volume":"100","author":"Poccia","year":"2005","journal-title":"Immunol. Lett."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Presti, E.L., De Gaetano, A., Pioggia, G., and Gangemi, S. (2022). Comprehensive Analysis of the ILCs and Unconventional T Cells in Virus Infection: Profiling and Dynamics Associated with COVID-19 Disease for a Future Monitoring System and Therapeutic Opportunities. Cells, 11.","DOI":"10.3390\/cells11030542"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1038\/s41467-020-19080-6","article-title":"Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19","volume":"11","author":"Carissimo","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11653","DOI":"10.1038\/ncomms11653","article-title":"MAIT cells are activated during human viral infections","volume":"7","author":"Scherwitzl","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11845-021-02653-9","article-title":"The role of unconventional T cells in COVID-19","volume":"191","author":"Orumaa","year":"2021","journal-title":"Ir. J. Med Sci."},{"key":"ref_12","first-page":"255","article-title":"Regulation of NKT Cell Localization in Homeostasis and Infection","volume":"6","author":"Eslauenwhite","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3109\/14653249.2012.700766","article-title":"Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells","volume":"14","author":"Knight","year":"2012","journal-title":"Cytotherapy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cellimm.2018.08.012","article-title":"V\u03b39V\u03b42 T cells proliferate in response to phosphoantigens released from erythrocytes infected with asexual and gametocyte stage Plasmodium falciparum","volume":"334","author":"Liu","year":"2018","journal-title":"Cell. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"eaay5516","DOI":"10.1126\/science.aay5516","article-title":"Butyrophilin 2A1 is essential for phosphoantigen reactivity by \u03b3\u03b4 T cells","volume":"367","author":"Rigau","year":"2020","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1042\/BST20200890","article-title":"Our evolving understanding of the role of the \u03b3\u03b4 T cell receptor in \u03b3\u03b4 T cell mediated immunity","volume":"49","author":"Gully","year":"2021","journal-title":"Biochem. Soc. Trans."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.immuni.2012.06.011","article-title":"\u03b3\u03b4 T Cells Recognize a Microbial Encoded B Cell Antigen to Initiate a Rapid Antigen-Specific Interleukin-17 Response","volume":"37","author":"Zeng","year":"2012","journal-title":"Immunity"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"eaba9010","DOI":"10.1126\/sciimmunol.aba9010","article-title":"Human \u03b3\u03b4 T cell sensing of AMPK-dependent metabolic tumor reprogramming through TCR recognition of EphA2","volume":"6","author":"Harly","year":"2021","journal-title":"Sci. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1073\/pnas.1621052114","article-title":"Sensing of cell stress by human \u03b3\u03b4 TCR-dependent recognition of annexin A2","volume":"114","author":"Marlin","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/ni.2394","article-title":"Cytomegalovirus and tumor stress surveillance by binding of a human \u03b3\u03b4 T cell antigen receptor to endothelial protein C receptor","volume":"13","author":"Willcox","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nature01433","article-title":"Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1","volume":"422","author":"Treiner","year":"2003","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1084\/jem.20031389","article-title":"Prevention of Autoimmunity by Targeting a Distinct, Noninvariant CD1d-reactive T Cell Population Reactive to Sulfatide","volume":"199","author":"Jahng","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/ecco-jcc\/jjy119","article-title":"Distinct Alterations in the Composition of Mucosal Innate Lymphoid Cells in Newly Diagnosed and Established Crohn\u2019s Disease and Ulcerative Colitis","volume":"13","author":"Forkel","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ecco-jcc\/jjz015","article-title":"Characterization of \u03b3\u03b4 T Cells in Intestinal Mucosa from Patients with Early-Onset or Long-Standing Inflammatory Bowel Disease and Their Correlation with Clinical Status","volume":"13","author":"Presti","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/mi.2015.69","article-title":"CD161(int)CD8+ T cells: A novel population of highly functional, memory CD8+ T cells enriched within the gut","volume":"9","author":"Fergusson","year":"2016","journal-title":"Mucosal Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/imr.12904","article-title":"Deciphering human \u03b3\u03b4 T cell response in cancer: Lessons from tumor-infiltrating \u03b3\u03b4 T cells","volume":"298","author":"Dieli","year":"2020","journal-title":"Immunol. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nm.4278","article-title":"A distinct innate lymphoid cell population regulates tumor-associated T cells","volume":"23","author":"Crome","year":"2017","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Allison, M., Mathews, J., Gilliland, T., and Mathew, S.O. (2022). Natural Killer Cell-Mediated Immunotherapy for Leukemia. Cancers, 14.","DOI":"10.3390\/cancers14030843"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/CJI.0000000000000171","article-title":"Significance of Frequencies, Compositions, and\/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL","volume":"40","author":"Boeck","year":"2017","journal-title":"J. Immunother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3389\/fimmu.2017.00573","article-title":"Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia","volume":"8","author":"Chretien","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: You can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.4049\/jimmunol.1500262","article-title":"Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion","volume":"195","author":"Khaznadar","year":"2015","journal-title":"J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3324\/haematol.2013.087536","article-title":"Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia","volume":"99","author":"Stringaris","year":"2014","journal-title":"Haematologica"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/ng.913","article-title":"Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia","volume":"43","author":"Hahn","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/ng.923","article-title":"Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome)","volume":"43","author":"Ostergaard","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1182\/blood-2012-09-453969","article-title":"Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56 bright subset","volume":"121","author":"Mace","year":"2013","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/bjc.1988.221","article-title":"Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in com-plete remission","volume":"58","author":"Pizzolo","year":"1988","journal-title":"Br. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.4049\/jimmunol.1200796","article-title":"Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses","volume":"189","author":"Hilpert","year":"2012","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.4049\/jimmunol.180.11.7249","article-title":"Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression","volume":"180","author":"Clayton","year":"2008","journal-title":"J. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3324\/haematol.2010.039743","article-title":"Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-\u03b21","volume":"96","author":"Szczepanski","year":"2011","journal-title":"Haematologica"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1889822","DOI":"10.1080\/2162402X.2021.1889822","article-title":"TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients","volume":"10","author":"Rakova","year":"2021","journal-title":"OncoImmunology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood-2018-03-838474","article-title":"Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function","volume":"132","author":"Scoville","year":"2018","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198704093161501","article-title":"A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone","volume":"316","author":"Rosenberg","year":"1987","journal-title":"New Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Innao, V., Allegra, A.G., Musolino, C., and Allegra, A. (2020). New Frontiers about the Role of Human Microbiota in Immunotherapy: The Immune Checkpoint Inhibitors and CAR T-Cell Therapy Era. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21238902"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bcmd.2016.11.001","article-title":"Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells","volume":"62","author":"Allegra","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-17-3196","article-title":"Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML","volume":"24","author":"Carlsten","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1158\/1078-0432.CCR-16-2981","article-title":"Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients","volume":"23","author":"Dolstra","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex vivo\u2013expanded donor-derived NK cells after haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100870","DOI":"10.1016\/j.mam.2020.100870","article-title":"NK cells and ILCs in tumor immunotherapy","volume":"80","author":"Sivori","year":"2021","journal-title":"Mol. Asp. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41409-021-01259-0","article-title":"Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: A study on behalf of the CTIWP of the EBMT","volume":"56","author":"Ruggeri","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1038\/s41409-021-01393-9","article-title":"Increased donor inhibitory KIR with known HLA interactions provide protection from relapse following HLA matched unrelated donor HCT for AML","volume":"56","author":"Krieger","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.imlet.2013.09.022","article-title":"Understanding human NK cell differentiation: Clues for improving the haploidentical hematopoietic stem cell transplantation","volume":"155","author":"Montaldo","year":"2013","journal-title":"Immunol. Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2014-03-563817","article-title":"HLA-haploidentical stem cell transplantation after removal of \u03b1\u03b2+ T and B cells in children with nonmalignant disorders","volume":"124","author":"Bertaina","year":"2014","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","article-title":"Outcome of children with acute leukemia given HLA-haploidentical HSCT after \u03b1\u03b2 T-cell and B-cell depletion","volume":"130","author":"Locatelli","year":"2017","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3389\/fimmu.2018.00984","article-title":"Human \u03b3\u03b4 T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias","volume":"9","author":"Pistoia","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.it.2018.04.009","article-title":"NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia","volume":"39","author":"Locatelli","year":"2018","journal-title":"Trends Immunol."},{"key":"ref_57","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: Safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2013-11-536888","article-title":"Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease","volume":"124","author":"Munneke","year":"2014","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.3324\/haematol.2014.119602","article-title":"CD127+ innate lymphoid cells are dysregulated in treatment na\u00efve acute myeloid leukemia patients at diagnosis","volume":"100","author":"Trabanelli","year":"2015","journal-title":"Haematologica"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/bloodadvances.2018030478","article-title":"CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML","volume":"3","author":"Loyon","year":"2019","journal-title":"Blood Adv."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1038\/s41375-020-0843-8","article-title":"Mesenchymal PGD2 activates an ILC2-Treg axis to promote proliferation of normal and malignant HSPCs","volume":"34","author":"Wu","year":"2020","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41467-017-00678-2","article-title":"Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis","volume":"8","author":"Trabanelli","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3892\/or.2016.5291","article-title":"Immature myeloid-derived suppressor cells: A bridge between inflammation and cancer","volume":"37","author":"Musolino","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1172\/JCI91816","article-title":"Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease","volume":"127","author":"Bruce","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1182\/bloodadvances.2020001514","article-title":"Third-party type 2 innate lymphoid cells prevent and treat GI tract GvHD","volume":"5","author":"Bruce","year":"2021","journal-title":"Blood Adv."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","article-title":"Innate Lymphoid Cells: 10 Years On","volume":"174","author":"Vivier","year":"2018","journal-title":"Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.bbmt.2014.09.010","article-title":"High-dose total body irradiation and myeloablative conditioning before allogeneic hematopoietic cell transplantation: Time to rethink?","volume":"21","author":"Mohty","year":"2015","journal-title":"Biol. Blood Marrow. Transpl."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nri2000","article-title":"Graft-versus-host disease","volume":"7","author":"Shlomchik","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1667\/RR14047.1","article-title":"Long-Lasting Impact of Neonatal Exposure to Total Body Gamma Radiation on Secondary Lymphoid Organ Structure and Function","volume":"184","author":"Biear","year":"2015","journal-title":"Radiat. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.1218004","article-title":"Interleukin-22 Drives Endogenous Thymic Regeneration in Mice","volume":"336","author":"Dudakov","year":"2012","journal-title":"Science"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/eji.201546079","article-title":"The generation of human innate lymphoid cells is influenced by the source of hematopoietic stem cells and by the use of G-CSF","volume":"46","author":"Moretta","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fimmu.2016.00188","article-title":"NK Cells and Other Innate Lymphoid Cells in Hematopoietic Stem Cell Transplantation","volume":"7","author":"Vacca","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cell.2017.07.027","article-title":"Regulatory Innate Lymphoid Cells Control Innate Intestinal Inflammation","volume":"171","author":"Wang","year":"2017","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.cell.2016.07.043","article-title":"The spectrum and regulatory landscape of intestinal innate lymphoid cells are shaped by the microbiome","volume":"166","author":"Thaiss","year":"2016","journal-title":"Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"10969","DOI":"10.2147\/CMAR.S234327","article-title":"Deficient Regulatory Innate Lymphoid Cells and Differential Expression of miRNAs in Acute Myeloid Leukemia Quantified by Next Generation Sequence","volume":"11","author":"Yu","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/08820139.2020.1806868","article-title":"Higher TIGIT+CD226- \u03b3\u03b4 T cells in Patients with Acute Myeloid Leukemia","volume":"51","author":"Jin","year":"2020","journal-title":"Immunol. Investig."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infil-trating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","article-title":"Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates","volume":"557","author":"Simoni","year":"2018","journal-title":"Nature"},{"key":"ref_80","first-page":"e1284723","article-title":"Assess-ment of Tumor-Infiltrating Tcrvg9vd2 gd Lymphocyte Abundance by Deconvolution of Human Cancers Microarrays","volume":"6","author":"Tosolini","year":"2017","journal-title":"Coimmunology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41423-020-0504-x","article-title":"Cancer immunotherapy with \u03b3\u03b4 T cells: Many paths ahead of us","volume":"17","author":"Kabelitz","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fimmu.2014.00636","article-title":"Clinical Applications of Gamma Delta T Cells with Multivalent Immunity","volume":"5","author":"Deniger","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_83","first-page":"81","article-title":"Efficacy and safety of gammadeltaT cell-based tumor im-munotherapy: A meta-analysis","volume":"28","author":"Buccheri","year":"2014","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/sj.bmt.1705650","article-title":"Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation","volume":"39","author":"Godder","year":"2007","journal-title":"Bone Marrow. Transpl."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood.V87.2.827.bloodjournal872827","article-title":"Lethal murine graft-versus-host disease induced by donor gamma\/delta expressing T cells with specificity for host nonclassical major his-tocompatibility complex class Ib antigens","volume":"87","author":"Blazar","year":"1996","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2004-10-4087","article-title":"Critical role of host \u03b3\u03b4 T cells in experimental acute graft-versus-host disease","volume":"106","author":"Maeda","year":"2005","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-016-0329-3","article-title":"Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells","volume":"9","author":"Anguille","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e1021538","DOI":"10.1080\/2162402X.2015.1021538","article-title":"Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy","volume":"4","author":"Anguille","year":"2015","journal-title":"OncoImmunology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3389\/fimmu.2018.00658","article-title":"Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion","volume":"9","author":"Anguille","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1158\/1078-0432.CCR-13-3451","article-title":"Activating and Propagating Polyclonal Gamma Delta T Cells with Broad Specificity for Malignancies","volume":"20","author":"Deniger","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia","volume":"11","author":"Rozenbaum","year":"2020","journal-title":"Front Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00262-021-03037-9","article-title":"MAIT cells numbers and frequencies in patients with acute myeloid leukemia at diagnosis: Association with cytogenetic profile and gene mutations","volume":"71","author":"Comont","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.3389\/fimmu.2017.01861","article-title":"Mucosal-Associated Invariant T Cells Display a Poor Reconstitution and Altered Phenotype after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"8","author":"Solders","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.20171739","article-title":"Ontogeny of human mucosal-associated invariant T cells and related T cell subsets","volume":"215","author":"Tourret","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12185-018-2442-2","article-title":"Influence of post-transplant mucosal-associated invariant T cell recovery on the development of acute graft-versus-host disease in allogeneic bone marrow transplantation","volume":"108","author":"Kawaguchi","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.4049\/jimmunol.1900681","article-title":"Reconstitution of Circulating Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation: Its Association with the Riboflavin Synthetic Pathway of Gut Microbiota in Cord Blood Transplant Recipients","volume":"204","author":"Konuma","year":"2020","journal-title":"J. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3389\/fimmu.2017.00717","article-title":"Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease","volume":"8","author":"Stikvoort","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"114970","DOI":"10.1016\/j.bcp.2022.114970","article-title":"Animal models of acute lymphoblastic leukemia: Recapitulating the human disease to evaluate drug efficacy and discover therapeutic targets","volume":"198","author":"Xin","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"ref_99","first-page":"3596983","article-title":"NK Cells as Possible Prognostic Factor in Childhood Acute Lymphoblastic Leukemia","volume":"2019","year":"2019","journal-title":"Dis. Markers"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1158\/1078-0432.CCR-14-0479","article-title":"NK Cell Genotype and Phenotype at Diagnosis of Acute Lymphoblastic Leukemia Correlate with Postinduction Residual Disease","volume":"20","author":"Sullivan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.4049\/jimmunol.166.12.7190","article-title":"Production of TNF-a by Human Vg9Vd2 T Cells Via Engagement of FcgRIIIA, the Low Affinity Type 3 Receptor for the Fc Portion of IgG, Expressed upon TCR Activation by Nonpeptidic An-tigen","volume":"166","author":"Lafont","year":"2001","journal-title":"J. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3389\/fimmu.2014.00618","article-title":"T Cell-Mediated Antibody-Dependent Cellular Cytotoxicity with CD19 Antibodies Assessed by an Impedance-Based Label-Free Real-Time Cytotoxicity Assay","volume":"5","author":"Seidel","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"83392","DOI":"10.18632\/oncotarget.13110","article-title":"CD19-specific triplebody SPM-1 engages NK and \u03b3\u03b4 T cells for rapid and efficient lysis of malignant B-lymphoid cells","volume":"7","author":"Schiller","year":"2016","journal-title":"Oncotarget"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","article-title":"Chronic myeloid leukaemia","volume":"398","author":"Cortes","year":"2021","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/blood.V88.6.2279.bloodjournal8862279","article-title":"CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis","volume":"88","author":"Pierson","year":"1996","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1182\/blood.V87.6.2476.bloodjournal8762476","article-title":"Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture","volume":"87","author":"Cervantes","year":"1996","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.1996.4991043.x","article-title":"Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR\/abl-positive targets","volume":"93","author":"Silla","year":"1996","journal-title":"Br. J. Haematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1002\/cam4.2371","article-title":"Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission","volume":"8","author":"Dumas","year":"2019","journal-title":"Cancer Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/leu.2011.180","article-title":"KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib","volume":"26","author":"Marin","year":"2012","journal-title":"Leukemia"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2015-07-655589","article-title":"KIR2DL5B genotype predicts out-comes in CML patients treated with response-directed sequential imatinib\/nilotinib strategy","volume":"126","author":"Yeung","year":"2015","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"729085","DOI":"10.3389\/fimmu.2021.729085","article-title":"\u03b3\u03b4 T Cells for Leukemia Immunotherapy: New and Expanding Trends","volume":"12","author":"Barros","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/14653240600620200","article-title":"Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of \u03b3\u03b4 T cells expanded from peripheral blood cells by stimulation with zoledronate","volume":"8","author":"Watanabe","year":"2006","journal-title":"Cytotherapy"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.4049\/jimmunol.0903454","article-title":"Vg9vd2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells","volume":"184","author":"Orlando","year":"2010","journal-title":"J. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Siegers, G.M., Felizardo, T.C., Mathieson, A.M., Kosaka, Y., Wang, X.-H., Medin, J.A., and Keating, A. (2011). Anti-Leukemia Activity of In Vitro-Expanded Human Gamma Delta T Cells in a Xenogeneic Ph+ Leukemia Model. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0016700"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Baumeister, J., Chatain, N., Sofias, A.M., Lammers, T., and Koschmieder, S. (2021). Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives. Cells, 10.","DOI":"10.3390\/cells10123551"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/1097-0142(19890901)64:5<1038::AID-CNCR2820640513>3.0.CO;2-W","article-title":"Decreased natural killer (NK) activity in patients with myeloproliferative dis-orders","volume":"64","author":"Froom","year":"1989","journal-title":"Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1521-6616(02)00046-3","article-title":"Impaired NK cell differentiation of blood-derived CD34+ progenitors from patients with myeloid metaplasia with myelofibrosis","volume":"106","author":"Briard","year":"2003","journal-title":"Clin. Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e1345402","DOI":"10.1080\/2162402X.2017.1345402","article-title":"Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis","volume":"6","author":"Romano","year":"2017","journal-title":"OncoImmunology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-0609.2010.01558.x","article-title":"Novel therapeutic strategies in multiple myeloma: Role of the heat shock protein inhibitors","volume":"86","author":"Allegra","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/ejh.12107","article-title":"Monoclonal antibodies: Potential new therapeutic treatment against multiple myeloma","volume":"90","author":"Allegra","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2141.1996.4651006.x","article-title":"Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications","volume":"93","author":"Moro","year":"1996","journal-title":"Br. J. Haematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e26011","DOI":"10.4161\/onci.26011","article-title":"Monitoring NK cell activity in patients with hematological malignancies","volume":"2","author":"Viel","year":"2013","journal-title":"OncoImmunology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/16078454.2021.2019365","article-title":"Prognostic significance of CD56 expression in patients with multiple myeloma: A meta-analysis","volume":"27","author":"Zhang","year":"2022","journal-title":"Hematology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s13046-019-1310-0","article-title":"IL-6 and IL-8 secreted by tu-mour cells impair the function of NK cells via the STAT3 pathway in oesophageal squamous cell carcinoma","volume":"38","author":"Wu","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00262-011-1064-9","article-title":"Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily through the PGE2 receptor EP4","volume":"60","author":"Holt","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/ijc.26152","article-title":"A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells","volume":"130","author":"Lin","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/cimm.1999.1586","article-title":"Interleukin-10 Reduces Natural Killer (NK) Sensitivity of Tumor Cells by Downregulating NK Target Structure Expression","volume":"198","author":"Tsuruma","year":"1999","journal-title":"Cell. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.bcp.2010.05.002","article-title":"PGE2 inhibits natural killer and \u03b3\u03b4 T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling","volume":"80","author":"Martinet","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1699-0463.1991.tb05159.x","article-title":"Immune dysfunction in multiple myeloma. Reduced natural killer cell activity and increased levels of soluble interleukin-2 receptors","volume":"99","author":"Nielsen","year":"1991","journal-title":"APMIS"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ctrv.2018.10.005","article-title":"Translating the anti-myeloma activity of Natural Killer cells into clinical application","volume":"70","author":"Fionda","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"100595","DOI":"10.1016\/j.blre.2019.100595","article-title":"The emerging role of exosomes in multiple myeloma","volume":"38","author":"Moloudizargari","year":"2019","journal-title":"Blood Rev."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: A therapeutic target for CT-011, a novel monoclonal anti\u2013PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"ref_135","first-page":"99","article-title":"Nat-ural killer cell frequency and function in patients with monoclonal gammopathies","volume":"37","author":"Famularo","year":"1992","journal-title":"J. Clin. Lab. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1080\/10428190500472503","article-title":"Immune parameters in multiple myeloma patients: Influence of treatment and correlation with opportunistic infections","volume":"47","author":"Brandhorst","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF00199953","article-title":"Surface markers and cytotoxic activities of lymphocytes in monoclonal gammopathy of undetermined significance and untreated multiple myeloma","volume":"25","author":"Bottari","year":"1987","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1182\/blood.V76.7.1375.1375","article-title":"Multiple myeloma: Increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival","volume":"76","author":"Omede","year":"1990","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2257.1994.tb00414.x","article-title":"Peripheral blood lymphocyte subsets in multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"16","author":"Tienhaara","year":"1994","journal-title":"Clin. Lab. Haematol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.leu.2404096","article-title":"Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma","volume":"20","author":"Fauriat","year":"2006","journal-title":"Leukemia"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12032-007-0007-y","article-title":"Clinical stage-depending decrease of NK cell activity in multiple myeloma patients","volume":"24","author":"Jurisic","year":"2007","journal-title":"Med Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/bloodadvances.2019000953","article-title":"Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules","volume":"4","author":"Barberi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"575609","DOI":"10.3389\/fimmu.2020.575609","article-title":"Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy","volume":"11","author":"Alfarra","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2009-02-206532","article-title":"Preclinical characterization of 1-7F9, a novel human anti\u2013KIR receptor therapeutic antibody that augments natural killer\u2013mediated killing of tumor cells","volume":"114","author":"Spee","year":"2009","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1182\/blood-2011-06-360255","article-title":"IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect","volume":"118","author":"Benson","year":"2011","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1182\/blood-2012-06-438028","article-title":"A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed\/refractory multiple myeloma","volume":"120","author":"Benson","year":"2012","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-15-0304","article-title":"A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"21","author":"Benson","year":"2015","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ni.3368","article-title":"The heterogeneity of human CD127+ innate lymphoid cells revealed by single-cell RNA sequencing","volume":"17","author":"Forkel","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_149","first-page":"4370","article-title":"Early Enrichment and Subsequent Dysfunction of Marrow ILC Subsets in Monoclonal Gammopathy: Target for IMiD Therapy","volume":"130","author":"Mehta","year":"2017","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Szudy-Szczyrek, A., Ahern, S., Kozio\u0142, M., Majowicz, D., Szczyrek, M., Krawczyk, J., and Hus, M. (2021). Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy. Cancers, 13.","DOI":"10.3390\/cancers13194806"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00262-019-02477-8","article-title":"The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide","volume":"69","author":"Sarkar","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/bloodadvances.2020002440","article-title":"Fc\u03b5RI\u03b3-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma","volume":"5","author":"Bigley","year":"2021","journal-title":"Blood Adv."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/imcb.12390","article-title":"Systemic administration of IL-33 induces a population of circulating KLRG1 hi type 2 innate lymphoid cells and inhibits type 1 innate immunity against multiple myeloma","volume":"99","author":"Guillerey","year":"2021","journal-title":"Immunol. Cell Biol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.leu.2403693","article-title":"Effector \u03b3\u03b4 T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma","volume":"19","author":"Mariani","year":"2005","journal-title":"Leukemia"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384.013k07_384_392","article-title":"Stimulation of gammadelta T cells by aminobi-sphosphonates and induction of antiplasma cell activity in multiple myeloma","volume":"96","author":"Kunzmann","year":"2000","journal-title":"Blood"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1158\/0008-5472.CAN-05-0731","article-title":"MICA Expressed by Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance Plasma Cells Costimulates Pamidronate-Activated \u03b3\u03b4 Lymphocytes","volume":"65","author":"Girlanda","year":"2005","journal-title":"Cancer Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.2007.06754.x","article-title":"In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma","volume":"139","author":"Condomines","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3324\/haematol.2011.056747","article-title":"Highly activated and expanded natural killer cells for multiple myeloma immunotherapy","volume":"97","author":"Garg","year":"2012","journal-title":"Haematologica"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/CJI.0000000000000059","article-title":"Ex Vivo\u2013expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients","volume":"38","author":"Szmania","year":"2015","journal-title":"J. Immunother."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.bbrc.2007.01.031","article-title":"\u03b3\u03b4T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface","volume":"354","author":"Uchida","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.18632\/oncotarget.13979","article-title":"Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and \u03b3\u03b4 T cell-mediated lysis in multiple myeloma","volume":"8","author":"Niu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: Evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-014-1610-3","article-title":"Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-\u03b1 pathways","volume":"64","author":"Balasa","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","article-title":"Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds","volume":"126","author":"Lagrue","year":"2015","journal-title":"Blood"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"26982","DOI":"10.18632\/oncotarget.4831","article-title":"Carfil-zomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotar-Get"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1038\/s41598-018-22130-1","article-title":"Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma","volume":"8","author":"Gherardin","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3109\/10428194.2015.1088653","article-title":"Innate-like T cell profile in myeloma: Severe deficiency of V\u03b39V\u03b42 T cells in aminobisphosphonate-treated patients","volume":"57","author":"Walsh","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"738915","DOI":"10.3389\/fimmu.2021.738915","article-title":"Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia","volume":"12","author":"Allegra","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.hoc.2013.01.003","article-title":"Understanding the immunodeficiency in chronic lymphocytic leukemia: Potential clinical impli-cations","volume":"27","author":"Riches","year":"2013","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/leu.2015.50","article-title":"Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis","volume":"29","author":"Wild","year":"2015","journal-title":"Leukemia"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Huergo-Zapico, L., Acebes-Huerta, A., Gonzalez-Rodriguez, A.P., Contesti, J., Gonzalez-Garc\u00eda, E., Payer, A.R., Vil-la-Alvarez, M., Fern\u00e1ndez-Guiz\u00e1n, A., L\u00f3pez-Soto, A., and Gonzalez, S. (2014). Expansion of NK cells and reduction of NKG2D expres-sion in chronic lymphocytic leukemia. Correlation with progressive disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0108326"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ijc.2910270310","article-title":"Deficiency of natural killer cell activity in patients with chronic lymphocytic leuke-mia","volume":"27","author":"Ziegler","year":"1981","journal-title":"Int. J. Cancer"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.leukres.2011.02.006","article-title":"Interleukin-21 and rituximab enhance NK cell functionality in patients with B-cell chronic lymphocytic leukaemia","volume":"35","author":"Eskelund","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2013-01-476606","article-title":"Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity","volume":"121","author":"Reiners","year":"2013","journal-title":"Blood"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.3324\/haematol.2016.144725","article-title":"Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia","volume":"101","author":"Munneke","year":"2016","journal-title":"Haematologica"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/cyto.b.21645","article-title":"Quantification and Phenotypic Characterization of Pe-ripheral Blood Vd1 + T Cells in Chronic Lymphocytic Leukemia and Monoclonal B Cell Lymphocytosis","volume":"96","author":"Silva","year":"2019","journal-title":"Cytom. Part B\u2014Clin. Cytom."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"9172","DOI":"10.1158\/0008-5472.CAN-04-2417","article-title":"V\u03b41 T Lymphocytes from B-CLL Patients Recognize ULBP3 Expressed on Leukemic B Cells and Up-Regulated by Trans-Retinoic Acid","volume":"64","author":"Poggi","year":"2004","journal-title":"Cancer Res."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3109\/14653249.2011.553595","article-title":"Human Vd1 gd T Cells Expanded from Peripheral Blood Exhibit Specific Cytotoxicity Against B-Cell Chronic Lymphocytic Leukemia-Derived Cells","volume":"13","author":"Siegers","year":"2011","journal-title":"Cytotherapy"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1158\/1078-0432.CCR-16-0597","article-title":"Delta One T Cells for Immunotherapy of Chronic Lymphocytic Leukemia: Clinical-Grade Expansion\/Differentiation and Preclinical Proof of Concept","volume":"22","author":"Almeida","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2012-03-417519","article-title":"Dysfunctional Vg9vd2 T Cells are Negative Prognosticators and Markers of Dysregulated Mevalonate Pathway Activity in Chronic Lymphocytic Leukemia Cells","volume":"120","author":"Coscia","year":"2012","journal-title":"Blood"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1182\/blood-2011-02-339135","article-title":"Differentiation of human peripheral blood V\u03b41+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells","volume":"118","author":"Correia","year":"2011","journal-title":"Blood"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood-2009-08-237123","article-title":"The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia\/lymphoma susceptibility to \u03b3\u03b4 T-cell cytotoxicity","volume":"115","author":"Correia","year":"2010","journal-title":"Blood"},{"key":"ref_184","first-page":"1271","article-title":"Improving CLL V\u03b39V\u03b42-T\u2013cell fitness for cellular therapy by ex vivo activation and ibrutinib","volume":"134","author":"Hofland","year":"2019","journal-title":"Blood"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"e1649971","DOI":"10.1080\/2162402X.2019.1649971","article-title":"Combined chemotherapy and allogeneic human V\u03b39V\u03b42 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells in vivo","volume":"8","author":"Joalland","year":"2019","journal-title":"OncoImmunology"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1182\/blood.V126.23.2914.2914","article-title":"Chronic Lymphocytic Leukemia (CLL) Cells Are Susceptible to \u03b3\u03b4-T Cell Mediated Killing, Provided CLL-Derived \u03b3\u03b4-T Cell Dysfunction Can be Reversed","volume":"126","author":"Terpstra","year":"2015","journal-title":"Blood"},{"key":"ref_187","first-page":"801","article-title":"Clinical relevance of NKT cells and soluble MIC-A in Hodgkin lymphoma","volume":"62","author":"Esparza","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/10428194.2017.1321751","article-title":"Increased frequencies of circulating and tumor-resident V?1 + T cells in patients with diffuse large B-cell lymphoma","volume":"59","author":"Reboursiere","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"3168172","DOI":"10.1155\/2022\/3168172","article-title":"Defining Diffuse Large B-Cell Lymphoma Immunotypes by CD8+ T Cells and Natural Killer Cells","volume":"2022","author":"Qi","year":"2022","journal-title":"J. Oncol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2013-10-533398","article-title":"CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets","volume":"123","author":"Gleason","year":"2014","journal-title":"Blood"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function","volume":"22","author":"Vallera","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1182\/bloodadvances.2018029371","article-title":"Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL","volume":"3","author":"Felices","year":"2019","journal-title":"Blood Adv."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","article-title":"A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells","volume":"35","author":"Arvindam","year":"2021","journal-title":"Leukemia"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41423-019-0247-8","article-title":"Vitamin C promotes the proliferation and effector functions of human \u03b3\u03b4 T cells","volume":"17","author":"Kouakanou","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Van Gorkom, G.N., Lookermans, E.L., Van Elssen, C.H., and Bos, G.M. (2019). The Effect of Vitamin C (Ascorbic Acid) in the Treatment of Patients with Cancer: A Systematic Review. Nutrients, 11.","DOI":"10.3390\/nu11050977"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.imlet.2018.11.004","article-title":"Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes?","volume":"201","author":"Vacca","year":"2018","journal-title":"Immunol. Lett."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/PPO.0000000000000156","article-title":"Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer","volume":"21","author":"Davis","year":"2015","journal-title":"Cancer J."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.bbmt.2016.08.008","article-title":"Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen\u2013Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute Leukemia","volume":"22","author":"Choi","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcyt.2020.09.010","article-title":"Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia","volume":"23","author":"Story","year":"2021","journal-title":"Cytotherapy"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.critrevonc.2015.06.003","article-title":"Vaccination of multiple myeloma: Current strategies and future prospects","volume":"96","author":"Allegra","year":"2015","journal-title":"Crit. Rev. Oncol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.leukres.2015.08.001","article-title":"Vaccination strategies in lymphoproliferative disorders: Failures and successes","volume":"39","author":"Allegra","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood-2010-06-288456","article-title":"A CpG-loaded tumor cell vaccine induces antitumor CD4 T cells that are effective in adoptive therapy for large and established tumors","volume":"117","author":"Goldstein","year":"2010","journal-title":"Blood"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1182\/blood-2012-04-426643","article-title":"NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma","volume":"120","author":"Mattarollo","year":"2012","journal-title":"Blood"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"771551","DOI":"10.3389\/fimmu.2021.771551","article-title":"Immune Cell-Derived Extracellular Vesicles\u2014New Strategies in Cancer Immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3389\/fimmu.2018.00998","article-title":"Zoledronate triggers V\u03b42 T cells to destroy and kill spheroids of colon carcinoma: Quantitative image analysis of three-dimensional cultures","volume":"9","author":"Varesano","year":"2018","journal-title":"Front. Immunol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/6\/754\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:20:06Z","timestamp":1760138406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/6\/754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":205,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["biom12060754"],"URL":"https:\/\/doi.org\/10.3390\/biom12060754","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,27]]}}}